ToddShaneCrocenziMD

Oncology • Portland, OR

Director of gastrointestinal oncology research at the Robert W. Franz Cancer Research Center principal investigator with the Columbia River Oncology Program

Join to view full profile

Dr. Crocenzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Crocenzi's full profile

Already have an account?

Office
4805 Ne Glisan St
6n40
Portland, OR 97213
Phone+1 503-215-5696

Fax+1 503-215-5695

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
University of MarylandResidency, Internal Medicine, 1994 - 1997
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1994

Certifications & Licensure

PA State Medical License Current
OR State Medical License 2005 - 2024

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Portland Monthly Magazine Castle Connolly, 2011
Join now to see all

Clinical Trials

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
Completed
Phase 1
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Immunochemoradiotherapy in Patients With Pancreatic Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 2
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C) Start of enrollment: 2013 Sep 01
Completed
Phase 2
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Immunoscore in Rectal Cancer Start of enrollment: 2014 Jan 24
Completed
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Start of enrollment: 2014 Mar 12
Active, not recruiting
Phase 2
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08
Completed
Phase 1
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma Start of enrollment: 2014 Oct 01
Completed
Phase 1
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Start of enrollment: 2016 Mar 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

904 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling
The New England Journal of Medicine. 2015-06-25
2860 citations
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S. Crocenzi, Masatoshi Kudo
Lancet. 2017-06-24
4429 citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne Bartlett
Science. 2017-07-28

Professional Memberships

American Society of Clinical Oncology - ASCO
Member